[Dependence of neuropeptide physiological effects on a route of administration].
Following intranasal administration, the peptides' effects could remain either the same as following an invasive administration (ACTH4-10) which is important for clinical application, or enhanced and prolonged (demorphin and argynilvasopressin analogue), or modified (beta-casomorphin-7). Techniques of improvement of the peptides' regulatory efficacy through protection against the protease action, are discussed. Peptide protection by introducing D-aminoacid's isomers into its molecule or addition of proline-rich sequences were compared. The latter technique seems to be more effective.
Kamenskiĭ
A A
AA
M. V. Lomonossov State University, 119899, Vorobievy Gory, Moscow, Russia.
Voskresenskaia
O G
OG
Dubynin
V A
VA
Levitskaia
N G
NG
D000281:Administration, Intranasal; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001127:Arginine Vasopressin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D004723:Endorphins / Q000008:administration & dosage / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000494:pharmacology; D009842:Oligopeptides / Q000008:administration & dosage* / Q000494:pharmacology; D018847:Opioid Peptides; D010147:Pain Measurement; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D004723:Endorphins; D018696:Neuroprotective Agents; D009842:Oligopeptides; D018847:Opioid Peptides; D010446:Peptide Fragments; D001127:Arginine Vasopressin; C030058:dermorphin; C041128:beta-casomorphin 7; C048487:ACTH (4-7), Pro-Gly-Pro-; D000324:Adrenocorticotropic Hormone